Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 546 shares, a decrease of 88.1% from the April 30th total of 4,577 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days. Approximately 0.0% of the shares of the stock are sold short.
Basilea Pharmaceutica Price Performance
Shares of BPMUF stock remained flat at $65.10 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.68 and a current ratio of 5.11. Basilea Pharmaceutica has a 12-month low of $57.70 and a 12-month high of $74.00. The stock has a 50-day moving average of $69.16 and a 200 day moving average of $67.53.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
- Palomar’s High-Risk Insurance Strategy Is Paying Off Big
- Marvell’s Pullback May Be the Setup Bulls Were Waiting For
- Flight Path to Profits: American Airlines Bets on SpaceX
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
